X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA FRESENIUS KABI ONCO. ELDER PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -0.2 22.1 - View Chart
P/BV x 0.1 3.1 3.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
FRESENIUS KABI ONCO.
Mar-13
ELDER PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs380176 215.9%   
Low Rs18879 239.5%   
Sales per share (Unadj.) Rs491.237.7 1,303.4%  
Earnings per share (Unadj.) Rs-3.25.1 -62.5%  
Cash flow per share (Unadj.) Rs14.46.7 214.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.542.5 885.0%  
Shares outstanding (eoy) m20.54158.23 13.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.4 17.1%   
Avg P/E ratio x-89.325.0 -357.3%  
P/CF ratio (eoy) x19.718.9 104.1%  
Price / Book Value ratio x0.83.0 25.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,83320,135 29.0%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,179703 309.9%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m10,0895,963 169.2%  
Other income Rs m25718 1,425.6%   
Total revenues Rs m10,3465,981 173.0%   
Gross profit Rs m-7921,430 -55.4%  
Depreciation Rs m361258 140.1%   
Interest Rs m2,756-26 -10,601.2%   
Profit before tax Rs m-3,6531,216 -300.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-68 -5,451.8%   
Tax Rs m125342 36.6%   
Profit after tax Rs m-65806 -8.1%  
Gross profit margin %-7.824.0 -32.7%  
Effective tax rate %-3.428.1 -12.2%   
Net profit margin %-0.613.5 -4.8%  
BALANCE SHEET DATA
Current assets Rs m9,2405,102 181.1%   
Current liabilities Rs m9,9982,385 419.1%   
Net working cap to sales %-7.545.6 -16.5%  
Current ratio x0.92.1 43.2%  
Inventory Days Days46150 30.9%  
Debtors Days Days60113 52.9%  
Net fixed assets Rs m10,1245,148 196.6%   
Share capital Rs m206158 130.0%   
"Free" reserves Rs m5,5826,556 85.2%   
Net worth Rs m7,7346,732 114.9%   
Long term debt Rs m4,889952 513.4%   
Total assets Rs m22,88210,388 220.3%  
Interest coverage x-0.3-45.8 0.7%   
Debt to equity ratio x0.60.1 446.9%  
Sales to assets ratio x0.40.6 76.8%   
Return on assets %11.87.5 156.6%  
Return on equity %-0.812.0 -7.1%  
Return on capital %22.314.6 152.8%  
Exports to sales %3.074.5 4.1%   
Imports to sales %0.424.8 1.7%   
Exports (fob) Rs m3074,441 6.9%   
Imports (cif) Rs m431,477 2.9%   
Fx inflow Rs m3075,298 5.8%   
Fx outflow Rs m1251,772 7.1%   
Net fx Rs m1813,525 5.1%   
CASH FLOW
From Operations Rs m11,7541,274 922.5%  
From Investments Rs m-561-1,204 46.5%  
From Financial Activity Rs m-6,762-196 3,448.1%  
Net Cashflow Rs m4,432-126 -3,508.9%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 16.8 9.6 175.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 9.1 396.7%  
Shareholders   16,479 42,599 38.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS